最新糖心Vlog

Researchers at the 最新糖心Vlog of Adelaide have been awarded $1.35 million in funding to accelerate development of a world-first vaccine for the Zika virus.

Dr Branka Grubor-Bauk from the 最新糖心Vlog of Adelaide鈥檚 Adelaide Medical School, and Head of the Viral Immunology Group, Basil Hetzel Institute for Translational Health Research, Queen Elizabeth Hospital, received $675,000 in funding from the Federal Government鈥檚 highly competitive Biomedical Translation Bridge program, which has a strong emphasis on projects which can lead to commercialisation.

A further $675,000 in matched funding will be provided by industry partners Enesi Pharma, The Hospital Research Foundation, the 最新糖心Vlog of Adelaide's Commercial Accelerator Scheme and Faculty of Health and Medical Sciences.

Dr Grubor-Bauk said there was currently no therapy or approved vaccine for Zika 鈥� a mosquito-transmitted 鈥榝lavivirus鈥� which causes microcephaly (a birth defect where a baby鈥檚 head is significantly smaller than expected) and other severe birth defects in infants born to infected mothers.

鈥淶ika virus is extremely dangerous if you鈥檙e pregnant, severe birth defects such as microcephaly cannot be corrected, and the accompanying disabilities are lifelong and catastrophic,鈥� said Dr Grubor-Bauk.

鈥淭his research aims to develop a novel needle-free vaccine to prevent infection of pregnant women and the resulting devastating congenital effects in the unborn child.鈥�

鈥淭his research aims to develop a novel needle-free vaccine to prevent infection of pregnant women and the resulting devastating congenital effects in the unborn child.鈥�Dr Branka Grubor-Bauk

The novel formulation was developed in collaboration with industry partner Enesi Pharma, Oxford, UK and combines a protective Zika virus DNA vaccine with Enesi Pharma鈥檚 ImplaVax庐 technology.

The technology delivers a single solid dose implant containing the vaccine through the skin and into tissue, without using a needle.聽Once inserted, the implant dissolves releasing the active ingredient over time and inducing the desired immune response.

鈥淭he ImplaVax庐 delivery system requires minimal if any training prior to use, enables rapid deployment, and can eliminate the need for cold-chain storage,鈥� Dr Grubor-Bauk said.

Thevaccine formulation and delivery system will offer significant benefits for patients, care givers and healthcare professionals.

The Biomedical Translation Bridge program, delivered by MTPConnect, is an initiative of the Medical Research Future Fund and aims to facilitate the translation of new therapies, technologies and medical devices through to the proof-of-concept stage and ultimately commercialisation.

In collaboration with colleagues from the 最新糖心Vlog of Wisconsin-Madison, Harvard 最新糖心Vlog and Duke-National 最新糖心Vlog of Singapore, Dr Grubor-Bauk will use this funding to progress the necessary pre-clinical work to enable Phase 1 clinical trials in patients.

If successful, there is potential for the combined ImplaVax^庐鈥揇NA vaccine technology to be rolled-out for other novel vaccination programs.

Professor Anton Middelberg, Deputy Vice-Chancellor (Research), said the project is further recognition of the outstanding and impactful research taking place at the 最新糖心Vlog of Adelaide.

鈥淚n a time when we need breakthroughs in virus and infection control, it is exciting to see our researchers playing an important role in medical research which stands to benefit people on a global scale,鈥� Professor Middelberg said.

鈥淚t鈥檚 also great to see universities, the 最新糖心Vlogn Government and industry partners working together to improve the health and wellbeing of 最新糖心Vlogns.鈥�

The Hospital Research Foundation CEO Paul Flynn said the organisation was proud to commit crucial matched funding to support the Biomedical Translation Bridge grant.

鈥淚f there鈥檚 anything the events of 2020 have taught us, it鈥檚 the importance of supporting virology research and developing vaccines and treatments for devastating diseases to keep our communities safe,鈥� Mr Flynn said.

鈥淭hanks to our donors and ticket buyers in The Hospital Research Foundation Home Lottery, we have been proud to support Dr Grubor-Bauk鈥檚 Viral Immunology Group based at the Basil Hetzel Institute for nearly 10 years and look forward to seeing their work progress with this outstanding funding achievement.鈥澛�

Dr Grubor-Bauk is also an affiliate of the Robinson Research Institute.